TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34741932

Group type: EXPERIMENTAL
Intervention: Cognitive dual task (CDT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Motor dual task (MDT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single task (ST)
Number of subjects: 53
Study: 34742157

Group type: EXPERIMENTAL
Intervention: BNT162b2 SARS-CoV-2 vaccination (two doses)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Active surveillance (control group)
Number of subjects: 291
Study: 34742314

Group type: EXPERIMENTAL
Intervention: Chimpanzees profile (high-MPA, low-inactivity, average-night-sleep)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Pandas profile (low-PA, high-inactivity, high-night-sleep)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Rabbits profile (very high-MPA/VPA, low-inactivity, average-night-sleep)
Number of subjects: 442
Study: 34742325

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Tai ji quan training
Number of subjects: 360

Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 360
Study: 34742327

Group type: EXPERIMENTAL
Intervention: Balanced/buffered crystalloids
Number of subjects: 8800

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 8800
Study: 34742328

Group type: EXPERIMENTAL
Intervention: 12-week resistance training program focusing on proximal and knee muscles using power and strength exercises
Number of subjects: 74

Group type: COMPARATOR
Intervention: 12-week resistance training program focusing on proximal and knee muscles using strength exercises only
Number of subjects: 74
Study: 34742578

Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Tumor BRCA testing
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 289
Study: 34743035

Group type: EXPERIMENTAL
Intervention: Fasting < 6 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fasting ≥ 6 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) within the last 48 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Absence of enteral nutrition (EN)
Number of subjects: 100
Study: 34743540

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5034
Study: 34743549

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (AVR)
Number of subjects: 33018
Study: 34743551

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 5648

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 5648

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 5648
Study: 34743565

Group type: EXPERIMENTAL
Intervention: RISTRA-ACS (risk stratification for acute coronary syndrome) implemented in 13 EDs
Number of subjects: 154914

Group type: COMPARATOR
Intervention: Control sites (8 EDs without RISTRA-ACS)
Number of subjects: 154914
Study: 34743701

Group type: EXPERIMENTAL
Intervention: eM2M intervention (12-week remotely delivered rhythmic exercise program)
Number of subjects: 108
Study: 34743729

Group type: EXPERIMENTAL
Intervention: COPD depressed patients (CD, n=27)
Number of subjects: 78

Group type: COMPARATOR
Intervention: COPD patients without depression (not explicitly mentioned in the abstract)
Number of subjects: 78
Study: 34743734

Group type: EXPERIMENTAL
Intervention: High homocysteine levels (highest tertile)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Patients with dNCR
Number of subjects: 175
Study: 34744427

Group type: EXPERIMENTAL
Intervention: Roflumilast (ROF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study: 34744669

Group type: EXPERIMENTAL
Intervention: Seated position interlimb coordination performance assessment
Number of subjects: 0
Study: 34744766

Group type: EXPERIMENTAL
Intervention: Different levels of variability in pressure support ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pressure support ventilation
Number of subjects: 0
Study: 34744825

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0
Study: 34744918

Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art-based Therapy (MCAT), a 6-week, 18-hours intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study: 34744972

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34744989

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34745093

Group type: EXPERIMENTAL
Intervention: Dornase alfa (inhaled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 34745199

Group type: EXPERIMENTAL
Intervention: Maternal plasma lipid concentrations
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Placental gene co-expression network analysis
Number of subjects: 64
Study: 34746196

Group type: EXPERIMENTAL
Intervention: Age-related hearing loss with tinnitus and physical frailty
Number of subjects: 0
Study: 34746207

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab treatment without Vitamin D3 supplementation
Number of subjects: 0
Study: 34746252

Group type: EXPERIMENTAL
Intervention: Walking activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 34746258

Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34746424

Group type: EXPERIMENTAL
Intervention: Individualized blood pressure management (maintaining systolic blood pressure at the level on presentation ±10 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized blood pressure management (systolic blood pressure target range 140-180 mmHg)
Number of subjects: 0
Study: 34746674

Group type: EXPERIMENTAL
Intervention: Volar Locking Plate
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: External Fixator
Number of subjects: 156
Study: 34746723

Group type: EXPERIMENTAL
Intervention: ORBCEL-C (100, 200, or 400 × 10^6 cells)
Number of subjects: 9
Study: 34746886

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Pembrolizumab (Cohort A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Pembrolizumab (Cohort B)
Number of subjects: 50
Study: 34746903

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg plus ezetimibe 10 mg fixed-dose combination (BA + EZE FDC)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 34746970

Group type: EXPERIMENTAL
Intervention: Pediatric age-specific PET template (PAPT)
Number of subjects: 130
Study: 34747267

Group type: EXPERIMENTAL
Intervention: Topical Oxygen Therapy (Natrox)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34747649

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34747691

Group type: EXPERIMENTAL
Intervention: Unattended sleep study with an auto-adjusting mandibular positioner
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Artificial intelligence method
Number of subjects: 58
Study: 34747699

Group type: EXPERIMENTAL
Intervention: Intrepid TMVR system
Number of subjects: 15
Study: 34747701

Group type: EXPERIMENTAL
Intervention: Sensor-Controlled Digital Game (SCDG) intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sensors-only intervention
Number of subjects: 38
Study: 34747704

Group type: EXPERIMENTAL
Intervention: NettOpp mobile app intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 34748144

Group type: EXPERIMENTAL
Intervention: COVID-19 players
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-COVID-19 players
Number of subjects: 42
Study: 34748385

Group type: EXPERIMENTAL
Intervention: Clofazimine, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34748572

Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (NECT)
Number of subjects: 629
Study: 34748634

Group type: EXPERIMENTAL
Intervention: Severe insulin-resistant diabetes (SIRD)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Severe autoimmune diabetes (SAID)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Glucose-tolerant control (CON)
Number of subjects: 746
Study: 34748672

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg intravenous every 24 weeks for 96 weeks
Number of subjects: 680
Study: 34748951

Group type: EXPERIMENTAL
Intervention: 50 ml Extra Virgin Olive Oil (EVOO) daily for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not administered EVOO (Control group)
Number of subjects: 0
Study: 34749516

Group type: EXPERIMENTAL
Intervention: Large Diameter Advanta V12 covered stent
Number of subjects: 70
Study: 34749638

Group type: EXPERIMENTAL
Intervention: Headache free participants
Number of subjects: 99

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 99
Study: 34749654

Group type: EXPERIMENTAL
Intervention: Saturday shift visits
Number of subjects: 16651

Group type: COMPARATOR
Intervention: Regular weekday shifts
Number of subjects: 16651

Group type: COMPARATOR
Intervention: Late weekday shifts
Number of subjects: 16651
Study: 34749756

Group type: EXPERIMENTAL
Intervention: COVID-19 critical illness
Number of subjects: 212
Study: 34749762

Group type: EXPERIMENTAL
Intervention: Multimodal intervention to target normoxia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 34749777

Group type: EXPERIMENTAL
Intervention: Personalized pharmaceutical plan (PPP) implemented in the intervention phase, including drug reconciliation, daily follow-up, and post-transplantation meetings.
Number of subjects: 1716

Group type: COMPARATOR
Intervention: Control phase with no personalized pharmaceutical plan.
Number of subjects: 1716
Study: 34749788

Group type: EXPERIMENTAL
Intervention: Home-based diabetes-modified behavioral activation treatment (HOME DM-BAT) using in-home, nurse telephone-delivered diabetes education and behavioral activation.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care group using in-home, nurse telephone-delivered health education/supportive therapy.
Number of subjects: 200
Study: 34749792

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Severe COVID-19 patients
Number of subjects: 105
Study: 34749816

Group type: EXPERIMENTAL
Intervention: QBSAfe agenda setting kit (ASK)
Number of subjects: 0
Study: 34749823

Group type: EXPERIMENTAL
Intervention: Intense leg resistance and dynamic exercise programme (up to six physiotherapy sessions over 3 months, home exercises at least three times per week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intense leg resistance and dynamic exercise programme
Number of subjects: 15
Study: 34749885

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor therapy
Number of subjects: 0
Study: 34750014

Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine based on prefusion-stabilized spike trimer with alum/CpG adjuvants
Number of subjects: 0
Study: 34750057

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant during induction phase (4 weeks)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant during optimization/maintenance phase (week 12)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs) during induction phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Serious TEAEs during induction phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: TEAEs of increased blood pressure during induction phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Falls during induction phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs) during optimization/maintenance phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Serious TEAEs during optimization/maintenance phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: TEAEs of increased blood pressure during optimization/maintenance phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Falls during optimization/maintenance phase
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 802
Study: 34750081

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously monthly (every 2 weeks if on apheresis)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 30
Study: 34750161

Group type: EXPERIMENTAL
Intervention: Airflow limitation in kidney transplant recipients
Number of subjects: 539

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 539
Study: 34750160

Group type: EXPERIMENTAL
Intervention: Long-term hemodialysis patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 22
Study: 34750296

Group type: EXPERIMENTAL
Intervention: Romidepsin (RMD) as latency-reversing agent
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (matched clinical characteristics, n=10)
Number of subjects: 15
Study: 34750494

Group type: EXPERIMENTAL
Intervention: Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parallel multi-arm multi-stage trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-arm trials in sequence with interim analyses
Number of subjects: 0
Study: 34750557

Group type: EXPERIMENTAL
Intervention: Durvalumab plus platinum-pemetrexed chemotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cisplatin and pemetrexed chemotherapy (historical control)
Number of subjects: 55
Study: 34750637

Group type: EXPERIMENTAL
Intervention: Dostarlimab 1, 3, or 10 mg/kg intravenously every 2 weeks (part 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks (Q3W)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dostarlimab 1000 mg every 6 weeks (Q6W)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dostarlimab (all doses)
Number of subjects: 34
Study: 34750642

Group type: EXPERIMENTAL
Intervention: Cranberry products consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical techniques (PCA, cluster analysis, PLS-DA)
Number of subjects: 0
Study: 34750648

Group type: EXPERIMENTAL
Intervention: 5-year ICU survivors performing a maximal CPET (N=313)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Controls (N=49)
Number of subjects: 361
Study: 34750659

Group type: EXPERIMENTAL
Intervention: HbA1c levels indicating pre-/diabetic state in patients undergoing major surgery
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Undiagnosed pre-/diabetic state
Number of subjects: 139
Study: 34750990

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan
Number of subjects: 440
Study: 34751002

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy (AST) discussion referrals
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Adjuvant sunitinib
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy trials
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Decision not to receive AST
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Referral frequency by individual surgeons
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Overall referral trends
Number of subjects: 618
Study: 34751159

Group type: EXPERIMENTAL
Intervention: Echocardiography and biomarkers assessment in patients with COVID-19
Number of subjects: 150
Study: 34751259

Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS vaccine (single intramuscular injection)
Number of subjects: 24
Study: 34751457

Group type: EXPERIMENTAL
Intervention: African-centered coping strategies
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 95
Study: 34751514

Group type: EXPERIMENTAL
Intervention: Parental obesity
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Parental elevated blood pressure/hypertension
Number of subjects: 280
Study: 34751617

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment
Number of subjects: 21
Study: 34751663

Group type: EXPERIMENTAL
Intervention: Foot-worn inertial measurement units (IMUs) for gait assessment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Foot-worn inertial measurement units (IMUs) for gait assessment with pain intensity as a covariate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 34751666

Group type: EXPERIMENTAL
Intervention: Purrble (interactive plush toy)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Active control (noninteractive plush toy)
Number of subjects: 134
Study: 34752208

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 34752484

Group type: EXPERIMENTAL
Intervention: Maier-Philip-6 HAMD subset scale
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Subset scales and full versions of HAMD
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Early improvement on subset scales and full versions
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Four HAMD-24 items
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: One HAMD-24 item
Number of subjects: 136
Study: 34752491

Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) and Deep Learning (DL) approaches applied to fetuses and newborns with CDH for predicting neonatal pulmonary hypertension (PH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) and Deep Learning (DL) approaches
Number of subjects: 0
Study: 34752714

Group type: EXPERIMENTAL
Intervention: Untreated opioid use
Number of subjects: 479

Group type: COMPARATOR
Intervention: Stable buprenorphine treatment
Number of subjects: 479
Study: 34752951

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Radiological procedure
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 201
Study: 34753208

Group type: EXPERIMENTAL
Intervention: Wearing surgical face masks during exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: No surgical face masks during exercise
Number of subjects: 32
Study: 34753292

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2411

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 2411
Study: 34753444

Group type: EXPERIMENTAL
Intervention: 3D methods of LA volume detection
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2D methods of LA volume detection
Number of subjects: 60
Study: 34753703

Group type: EXPERIMENTAL
Intervention: Cetuximab added to first-line chemotherapy (CT) in SCC patients with positive EGFR FISH and IHC (N=58)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Cetuximab added to CT in SCC patients
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Control group (CT without cetuximab) in SCC patients
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Cetuximab added to CT in Non-SCC patients
Number of subjects: 1313
Study: 34753762

Group type: EXPERIMENTAL
Intervention: Daily administration of an unspecified intervention (not detailed in the abstract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 34753777

Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1 mg/kg plus Nivolumab 240 mg
Number of subjects: 114
Study: 34753871

Group type: EXPERIMENTAL
Intervention: Digital pill system (DPS)
Number of subjects: 16
Study: 34753870

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) interruption after achieving >99.5% host cell replacement in peripheral blood by day 147.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Pre-alloBMT HIV DNA and cell-associated RNA isolation from peripheral blood mononuclear cells and resting memory CD4+ T cells.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Viral rebound sequences from plasma and CSF.
Number of subjects: 1
Study: 34753894

Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine (Moderna) - 2 doses
Number of subjects: 800
Study: 34754076

Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of plasmids encoding IL-12 and anti-PD-1 antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple combination of IL-12, anti-PD-1, and anti-CTLA-4 antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA-based immunotherapies
Number of subjects: 0
Study: 34754193

Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride (SH) 2,400 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lanthanum Carbonate (LC) 1,000 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both SH and LC
Number of subjects: 34
Study: 34754421

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous monitoring for postoperative complications
Number of subjects: 0
Study: 34754429

Group type: EXPERIMENTAL
Intervention: ADPKD-specific pain assessment tool (APAT) administered longitudinally in a randomized high-water intake trial.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pain severity and associated analgesic use in ADPKD participants.
Number of subjects: 39
Study: 34755128

Group type: EXPERIMENTAL
Intervention: Winter swimming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34755131

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab treatment
Number of subjects: 12
Study: 34755137

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered biweekly for 3 to 4 doses before surgery
Number of subjects: 12
Study: 34755248

Group type: EXPERIMENTAL
Intervention: PET/MRI features in patients with metastases
Number of subjects: 101

Group type: COMPARATOR
Intervention: PET/MRI features in patients without metastases
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MRI features
Number of subjects: 101
Study: 34755317

Group type: EXPERIMENTAL
Intervention: Attentional bias to threat
Number of subjects: 0
Study: 34755598

Group type: EXPERIMENTAL
Intervention: Obesity as a risk factor for pulmonary hypertension (PH) in untreated obesity hypoventilation syndrome (OHS)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions targeting weight loss
Number of subjects: 246